#1 Clinical Trials Search in Europe

Bt-001

BT-001 is an innovative drug currently being studied in clinical trials for patients with advanced solid tumors. This article explores the ongoing research on BT-001, its potential benefits, and its use in combination with pembrolizumab for treating various types of cancer, including soft tissue sarcoma, Merkel cell carcinoma, melanoma, triple-negative breast cancer, and non-small cell lung cancer.

Table of Contents

What is BT-001?

BT-001, also known as TG6030, is an innovative medication being studied for the treatment of advanced solid tumors[1]. It is a type of oncolytic virus, which means it’s a virus that has been modified to target and kill cancer cells while leaving healthy cells unharmed. BT-001 is administered as a suspension for injection, typically given directly into the tumor (intratumoral injection)[1].

How does BT-001 work?

BT-001 is designed to work in two ways:

  1. It directly attacks and kills cancer cells.
  2. It stimulates the patient’s immune system to fight against the cancer.
The medication contains a modified form of the vaccinia virus, which has been engineered to produce two important substances:
  • GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor): This helps activate immune cells to fight the cancer.
  • Anti-CTLA-4 antibody: This is a type of immunotherapy that helps boost the body’s immune response against cancer cells.
By combining these approaches, BT-001 aims to provide a powerful treatment option for patients with advanced cancers[1].

What conditions does BT-001 treat?

BT-001 is being studied for the treatment of several types of advanced or metastatic solid tumors, including:

  • Soft tissue sarcoma (STS): A type of cancer that develops in soft tissues like muscles, fat, or blood vessels.
  • Merkel cell carcinoma (MCC): A rare but aggressive type of skin cancer.
  • Melanoma: A serious type of skin cancer that develops in melanocytes (pigment-producing cells).
  • Triple negative breast cancer (TNBC): An aggressive form of breast cancer that lacks certain receptors, making it harder to treat with standard therapies.
  • Non-small cell lung cancer (NSCLC): The most common type of lung cancer.
These cancers are considered advanced or metastatic, meaning they have spread beyond their original location[1].

Clinical Trial Overview

BT-001 is currently being studied in a Phase I/IIa clinical trial. This trial is designed to:

  1. Assess the safety and tolerability of BT-001 when given alone and in combination with another immunotherapy drug called pembrolizumab.
  2. Determine the best dose of BT-001 to use.
  3. Evaluate how effective BT-001 is in treating the targeted cancers.
The trial is divided into different parts:
  • Phase I, Part A: Testing BT-001 alone to determine its safety and the right dose to use.
  • Phase I, Part B: Testing BT-001 in combination with pembrolizumab to assess safety and tolerability.
  • Phase II: Evaluating how well BT-001 combined with pembrolizumab works in treating the targeted cancers[1].

Eligibility Criteria

To participate in this clinical trial, patients must meet certain criteria. Some key eligibility requirements include:

  • Being 18 years or older
  • Having a confirmed diagnosis of one of the targeted cancers (STS, MCC, melanoma, TNBC, or NSCLC)
  • Having tumors that can be easily injected (such as those on or just under the skin, or in easily accessible lymph nodes)
  • Having tried and not responded to standard treatments, or being unable to tolerate standard treatments
  • Being in relatively good overall health (able to perform daily activities with minimal assistance)
There are also several factors that might prevent someone from participating in the trial, such as having certain other medical conditions or having received specific treatments recently[1].

Potential Benefits and Risks

As with any experimental treatment, BT-001 may offer potential benefits but also carries risks: Potential Benefits:

  • It may help shrink tumors or slow cancer growth in patients who haven’t responded to other treatments.
  • It might stimulate the immune system to fight cancer more effectively.
  • It could potentially lead to longer survival or improved quality of life for some patients.
Potential Risks:
  • As a virus-based therapy, it might cause flu-like symptoms or other side effects.
  • There’s a risk of overstimulating the immune system, which could lead to autoimmune-like side effects.
  • As with any new treatment, there may be unknown risks or side effects that haven’t been discovered yet.
It’s important to discuss these potential benefits and risks thoroughly with a healthcare provider before considering participation in the clinical trial[1].

Aspect Details
Drug Name BT-001 (TG6030)
Administration Method Intratumoral injection
Target Cancers Soft tissue sarcoma, Merkel cell carcinoma, melanoma, triple-negative breast cancer, non-small cell lung cancer
Trial Phase Phase I/IIa
Main Objectives Assess safety, tolerability, determine maximum tolerated dose, evaluate antitumor activity
Combination Therapy BT-001 with pembrolizumab
Key Eligibility Criteria Adults 18+, confirmed advanced/metastatic cancer, failed standard treatments, injectable tumor lesion
Primary Endpoints Adverse events, progression-free rate, immune overall response rate

FAQ

  • What is BT-001 and how is it administered? BT-001 is an investigational drug administered through intratumoral injections. It is being studied for its potential to treat advanced solid tumors, either alone or in combination with pembrolizumab.
  • What types of cancer are being targeted in the BT-001 clinical trials? The clinical trials are focusing on patients with metastatic or advanced soft tissue sarcoma (STS), Merkel cell carcinoma (MCC), melanoma, triple-negative breast cancer (TNBC), and non-small cell lung cancer (NSCLC).
  • What are the main objectives of the BT-001 clinical trials? The main objectives include assessing the safety and tolerability of BT-001, determining the maximum tolerated dose, and evaluating its antitumor activity when used alone and in combination with pembrolizumab.
  • Who is eligible to participate in the BT-001 clinical trials? Eligible participants are adults aged 18 or older with confirmed advanced or metastatic cancer of the specified types, who have failed or are intolerant to standard treatments, and have at least one injectable tumor lesion.
  • What are some of the key exclusion criteria for the BT-001 clinical trials? Key exclusion criteria include having active CNS metastases, severe hypersensitivity to pembrolizumab, active autoimmune diseases, HIV infection, active Hepatitis B or C, and having received certain prior treatments such as live vaccines within 30 days of the study.

Ongoing Clinical Trials on Bt-001

  • Study of BT-001 and Pembrolizumab for Patients with Advanced Solid Tumors, Including Sarcoma, Merkel Cell Carcinoma, Melanoma, Breast, and Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France

Glossary

  • Intratumoral (IT): A method of administering medication directly into a tumor.
  • Pembrolizumab: An immunotherapy drug used in combination with BT-001 in some parts of the clinical trial.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Soft Tissue Sarcoma (STS): A type of cancer that develops in soft tissues like muscles, tendons, and fat.
  • Merkel Cell Carcinoma (MCC): A rare type of skin cancer that usually appears as a flesh-colored or bluish-red nodule on the skin.
  • Melanoma: A serious type of skin cancer that develops in the cells that produce melanin.
  • Triple Negative Breast Cancer (TNBC): A type of breast cancer that lacks three common receptors, making it harder to treat with standard therapies.
  • Non-Small Cell Lung Cancer (NSCLC): A type of lung cancer that is the most common form of the disease.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that does not cause unacceptable side effects.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body.
  • Tumor Microenvironment: The area surrounding a tumor, including blood vessels, immune cells, and signaling molecules.
  • Viral Shedding: The release of virus particles from an infected person, which can potentially spread the virus to others.

References

  1. http://clinicaltrials.eu/trial/study-of-bt-001-and-pembrolizumab-for-patients-with-advanced-solid-tumors-including-sarcoma-merkel-cell-carcinoma-melanoma-breast-and-lung-cancer/